糖化血红蛋白首次达标时间切点的研究

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the intensive treatment time for control of glycosylated hemoglobin in diabetic patients with intensive blood glucose control for the first time.Methods Patients were collected who were hospitalized for the first time in the Department of Endocrinology of Shengzhou People′s Hospital (hereinafter referred to as "our hospital") for intensive blood glucose control from September 2017 to December 2019,and returned to our hospital within 120 days from the date of intensive blood glucose control.According to the diabetes diagnosis and treatment guidelines,glycosylated hemoglobin＜7% was considered as blood glucose control meeting the standard.Results A total of 119 patients revisited within 120 days from the date of intensive blood glucose control,including 80 males and 39 females.The age ranged from 19 to 85 years old,with an average age of (50.7±14.3) years old.The interval time of first followup visit was (70.8±25.7) days.The first time to reach the blood glucose standard occurred on the forty-fifth day after the initiation of intensive control of blood glucose.The cut-off point for the control of glycosylated hemoglobin within the normal range occurred on the fifty-ninth day of the first intensive blood glucose control.Conclusion The cut-off point of the earliest revisit for glycosylated hemoglobin control meeting the standard is the forty-fifth day from the initiation of intensive blood glucose control.The earliest cut-off point for revisit when the glycosylated hemoglobin is fully controlled within the normal range is the sixtieth day from the initiation of intensive control of blood glucose.There is no clinical significance when rechecking glycosylated hemoglobin within 45 days from the initiation of intensive blood glucose control.

Key words： Diabetes Glycosylated hemoglobin Initial diagnosis and treatment Chronic hyperglycemia Cut-off point;Intensive control of blood sugar

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I5/71

[1]	中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017版）[J].中国实用内科杂志，2018，38（4）：292-344.
[2]	Rahbar S.An abnormal hemoglobin in red cells of diabetics[J].Clin Chim Scta，1968，22（2）：297-298.
[3]	张景义，郭静，董钊，等.糖化血红蛋白和空腹血糖早期诊断糖尿病的截点研究[J].中国全科医学，2017，20（7）：808-811，822.
[4]	Dozio E，Di Gaetano N，Findeisen P，et al.Glycated albumin：from biochemistry and laboratory medicine to clinical practice[J].Endocrine，2017，55：682-690.
[5]	Zhang XW，Zhang XL，Xu B，et al.Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes：a meta-analysis of randomized controlled trials[J].Acta Diabetol，2018，55（5）：429-441.
[6]	Nathan DM，Turgeon H，Regan S.Relationship between glycated hemoglobin levels and mean glucose levels over time[J].Diabetologia，2007，50：2239-2244.
[7]	Schnell O，Crocker JB，Weng J.Impact of HbA1c Testing at Point of Care on Diabetes Management[J].J Diabetes Sci Technol，2017，11（3）：611-617.
[8]	International Expert Committee.International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes[J].Diabetes Care，2009，32：1327-1334.
[9]	He X，Mo Y，Ma X，et al.Associations of body mass index with glycated albumin and glycated albumin/glycated hemoglobin A1c ratio in Chinese diabetic and non-diabetic populations[J].Clin Chim Acta，2018，484：117-121.
[10]	杨彩娴，黄启亚，钟国权，等.新诊断2型糖尿病患者早期胰岛素强化治疗后续治疗方案的随访研究[J].中国糖尿病杂志，2017，25（5）：397-402.
[11]	唐娟，李卿，邓爽，等.对α 地中海贫血Hb H 病糖化血红蛋白不同检测方法结果的分析[J].中国糖尿病杂志，2018，26（3）：193-196.
[13]	王柏荣，陆志强，李晓牧，等.新发暴发型1型糖尿病中糖化白蛋白/HbA1C 比值与血糖波动幅度的相关性研究[J].中华内分泌代谢杂志，2017，33（4）：326-329.
[14]	马春芳，沈国荣，陆小芳，等.血清C 肽与糖化血红蛋白联合检测对糖尿病诊断的临床意义[J].临床合理用药杂志，2017，10（1）：113-114.
[12]	UK Prospective diabetes Study （UKPDS）Group.Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes（UKPDS 33）[J].Lancet，1998，352：837-853.
[15]	Zhao Z，Li X，Jian D，et al.Hsa circ 0054633 in peripheral blood can be used as a diagnostic biomarker of pre-diabetes and type 2 diabetes mellitus[J].Acta Diabetologica，2017，54（3）：237-245.
[16]	Selvin E，Marinopoulos S，Berkenblit G，et al.Meta-annlysis glycosylated hemoglobin and cardiovascular disease in diabetes mellitus[J].Ann Intern Med，2004，141（6）：421-431.
[17]	Wang Y，Yuan Y，Zhang Y，et al.Serum 1，5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes[J].Acta Diabetologica，2017，54（5）：1-7.
[18]	Malekian A，Esmaeeli Djavid G，Akbarzadeh K，et al.Efficacy of Maggot Therapy on Staphylococcus aureus and Pseudomonas aeruginosa in Diabetic Foot Ulcers：A Randomized Controlled Trial[J].J Wound Ostomy Cont Nurs，2019，46（1）：25-29.
[19]	American Diabetes Association.Standards of Medical Care in Diabetes-2017[J].Diabetes Care，2017，40（Suppl 1）：S1-135.
[20]	American Diabetes Association.Standards of medical care in diabetes[J].Diabetes Care，2009，32（Suppl 1）：S13-S61.